Literature DB >> 22820646

Impact of lyoprotectants for the stabilization of biodegradable nanoparticles on the performance of air-jet, ultrasonic, and vibrating-mesh nebulizers.

Moritz Beck-Broichsitter1, Pia Kleimann, Thomas Schmehl, Thomas Betz, Udo Bakowsky, Thomas Kissel, Werner Seeger.   

Abstract

Strategies for further advancements in pulmonary drug delivery include the application of colloidal carriers. Freeze-drying in the presence of lyoprotectants is a valuable approach to improve long-term stability of biodegradable nanoparticles, but possibly constrains aerosol generation after powder rehydration, when employing traditional nebulizers. Here, we investigated the impact of lyoprotectants on both output and aerodynamic performance of air-jet, ultrasonic, and vibrating-mesh nebulization. Additionally, changes in formulation temperature and concentration were monitored, to estimate physicochemical alterations of formulations during nebulization. The stability of poly(d,l-lactide-co-glycolide) nanoparticles was maintained for lyoprotectant/nanoparticle ratios above 5/1. All nebulized formulations displayed suitable output and aerodynamic characteristics for peripheral lung deposition. Air-jet- and ultrasonic nebulization was associated with considerable temperature (~10°C) and concentration changes (up to 156%) of the reservoir fluid, which consequently, caused significant shifting of surface tension and viscosity. By contrast, vibrating-mesh nebulization caused marginal temperature increase (~5°C) with no apparent signs of concentration. Thus, the changing surface tension and viscosity were fitted employing Eötvös' rule and the Andrade equation (R(2)>0.98), allowing to predict the physicochemical properties of each formulation for prolonged nebulization periods. In particular, vibrating-mesh nebulization seems to be promising for aerosol application of rehydrated freeze-dried biodegradable nanoparticles to the respiratory tract.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22820646     DOI: 10.1016/j.ejpb.2012.07.004

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  8 in total

1.  MAbDelivery: Administration routes for antibody therapy Third LabEx MAbImprove industrial workshop, July 2, 2015 Tours, France.

Authors:  Elsa Bodier-Montagutelli; Renaud Respaud; Hervé Watier; Audrey Guillon-Munos
Journal:  MAbs       Date:  2017-02-28       Impact factor: 5.857

2.  Nebulization of Single-Chain Tissue-Type and Single-Chain Urokinase Plasminogen Activator for Treatment of Inhalational Smoke-Induced Acute Lung Injury.

Authors:  Soraya Hengsawas Surasarang; Sawittree Sahakijpijarn; Galina Florova; Andrey A Komissarov; Christina L Nelson; Enkhbaatar Perenlei; Satoshi Fukuda; Marla R Wolfson; Thomas H Shaffer; Steven Idell; Robert O Williams
Journal:  J Drug Deliv Sci Technol       Date:  2018-04-30       Impact factor: 3.981

3.  Gelatin Stabilizes Nebulized Proteins in Pulmonary Drug Delivery against COVID-19.

Authors:  Chunlin Li; Ira Marton; Daniel Harari; Maya Shemesh; Vyacheslav Kalchenko; Michal Pardo; Gideon Schreiber; Yinon Rudich
Journal:  ACS Biomater Sci Eng       Date:  2022-05-24

4.  In vitro evaluation of the inhalable quercetin loaded nanoemulsion for pulmonary delivery.

Authors:  Noor Hafizah Arbain; Norazlinaliza Salim; Hamid Reza Fard Masoumi; Tin Wui Wong; Mahiran Basri; Mohd Basyaruddin Abdul Rahman
Journal:  Drug Deliv Transl Res       Date:  2019-04       Impact factor: 4.617

5.  Nebulised Gadolinium-Based Nanoparticles for a Multimodal Approach: Quantitative and Qualitative Lung Distribution Using Magnetic Resonance and Scintigraphy Imaging in Isolated Ventilated Porcine Lungs.

Authors:  Yoann Montigaud; Jérémie Pourchez; Lara Leclerc; Olivier Tillement; Anthony Clotagatide; Clémence Bal; Noël Pinaud; Nobuyasu Ichinose; Bei Zhang; Sophie Perinel; François Lux; Yannick Crémillieux; Nathalie Prevot
Journal:  Int J Nanomedicine       Date:  2020-09-30

6.  Generation of a Nebulizable CDR-Modified MERS-CoV Neutralizing Human Antibody.

Authors:  Sang Il Kim; Sujeong Kim; Jinhee Kim; So Young Chang; Jung Min Shim; Jongwha Jin; Chungsu Lim; Songyi Baek; Ji-Young Min; Wan Beom Park; Myoung-Don Oh; Seungtaek Kim; Junho Chung
Journal:  Int J Mol Sci       Date:  2019-10-12       Impact factor: 5.923

Review 7.  Nanoapproaches to Modifying Epigenetics of Epithelial Mesenchymal Transition for Treatment of Pulmonary Fibrosis.

Authors:  Melissa Skibba; Adam Drelich; Michael Poellmann; Seungpyo Hong; Allan R Brasier
Journal:  Front Pharmacol       Date:  2020-12-11       Impact factor: 5.810

8.  Characteristics, Cryoprotection Evaluation and In Vitro Release of BSA-Loaded Chitosan Nanoparticles.

Authors:  Qinying Yan; Jiaqi Weng; Xieqi Wu; Weiwei Wang; Qingliang Yang; Fangyuan Guo; Danjun Wu; Ying Song; Fan Chen; Gensheng Yang
Journal:  Mar Drugs       Date:  2020-06-15       Impact factor: 5.118

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.